drugset / Trial / NCT02333513

A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation

NCT02333513

NaSingle-groupOpen-labelTreatment

Summary

This trial is aimed at evaluating the safety and effectiveness of PCV chemotherapy in patients with recurrent high-grade glioma with IDH1/2 mutation.

Timeline

Start
2015-02
Primary completion
2017-12
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lomustine Small molecule
Subject Vincristine Small molecule
Subject procarbazine Small molecule

Indications